Cipla Ltd, the Mumbai-headquartered global pharmaceutical major, is stepping up investments in innovation, artificial intelligence, biosimilars and strategic acquisitions as it looks to strengthen its position across key global markets and build a future-ready organisation.
India will remain a key growth driver, with the company focusing on therapy areas including respiratory, cardiology, diabetology, urology, oncology, dermatology, gastroenterology and central nervous system disorders.
Focus on key markets
“Looking ahead, our focus remains on strengthening execution to sustain growth while building leadership across India, US, EMEU and Africa,” said Managing Director and Global Chief Executive Officer Achin Gupta in the latest annual report.
“In India, we will deepen our presence in key chronic therapies while sustaining leadership in respiratory. We will continue to invest in biosimilars and scale our complex inhalation capabilities in the US,” he said.
“In South Africa, we will prioritise the private segment, while in EMEU we will drive growth through deeper market penetration with disciplined margins.”
Innovation and AI-led transformation
Globally, Cipla will prioritise respiratory and immunology, while oncology and anti-infectives will remain focus areas across India and emerging markets. The company is also expanding its differentiated pipeline through investments in injectables, peptides and other specialised therapies.
“We are also accelerating our AI-led transformation, supported by investments in data and technology platforms, to enhance efficiency, strengthen decision-making and unlock long-term value,” Gupta said.
“In a dynamic environment, agility, disciplined execution and acting early will define our next phase of growth.”
Building future capabilities
Cipla is advancing next-generation modalities, including oligonucleotides and biosimilars, supported by focused R&D investments and strategic collaborations.
“These efforts reinforce our shift towards complex, science-led therapies while remaining anchored in our generics foundation,” Gupta said.
To strengthen India’s respiratory healthcare ecosystem, the Cipla Foundation has partnered with Tata-IISc Medical School in Bengaluru to establish a state-of-the-art Pulmonary Medicine Centre focused on early diagnosis, advanced research and skill development.
Capital allocation priorities
The company plans to expand its product pipeline through both organic and inorganic routes while selectively pursuing acquisitions in India and the United States. It also intends to deepen its presence across the Europe, Middle East and Africa region as part of its long-term growth strategy.
“Our purpose of ‘Caring for Life’ is the heartbeat of Cipla. It shapes every innovation we pioneer, every partnership we forge and every life we touch,” he said.